Lucentis in Advanced Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Macular Degeneration
Interventions
DRUG

ranibizumab

"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"

Trial Locations (2)

94107

California Pacific Medical Center, San Francisco

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

California Pacific Medical Center

OTHER

collaborator

Pacific Eye Associates

OTHER

lead

Steven R. Sanislo

OTHER

NCT00896779 - Lucentis in Advanced Macular Degeneration | Biotech Hunter | Biotech Hunter